Screener
Cartesian Therapeutics, Inc. RNAC Q3 2025 earnings
Reported November 6, 2025 · Before market open
Revenue$452.0KBeat by $351.8K
EPS-$1.38Miss by $0.57
Revenue estimate$100.2K
EPS estimate-$0.81
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$180.0K
EPS estimate-$1.02
Versus estimates
Revenue
Q1 2026$78.0KMiss by $141.8KQ4 2025$947.0KBeat by $796.7K
Q3 2025$452.0KBeat by $351.8K
Q2 2025$298.0KBeat by $120.4KQ1 2025$1.1MBeat by $412.5KDiluted EPS
FAQ
- When did Cartesian Therapeutics, Inc. report Q3 2025 earnings?
- Cartesian Therapeutics, Inc. (RNAC) reported Q3 2025 earnings on November 6, 2025 before market open.
- What were Cartesian Therapeutics, Inc.'s Q3 2025 revenue and EPS?
- Cartesian Therapeutics, Inc. reported revenue of $452.0K and eps of $-1.38 for Q3 2025.
- Did Cartesian Therapeutics, Inc. beat estimates in Q3 2025?
- Revenue beat the consensus estimate of $100.2K by $351.8K. EPS missed the consensus estimate of $-0.81 by $0.57.
- How did Cartesian Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 16.8% from $387.0K a year earlier and eps declined 100.0% from $-0.69.
- Where can I find Cartesian Therapeutics, Inc.'s Q3 2025 SEC filings?
- You can read the 8-K earnings release (0001453687-25-000119) and the 10-Q periodic report (0001453687-25-000120) directly on SEC EDGAR. The filing index links above go to sec.gov.
